Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2012. The report details a specific share repurchase transaction executed on October 9, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, or debt levels. It focuses exclusively on capital structure and treasury share activity.
- Shares Purchased: 490,000 Ordinary Shares of 25 pence each.
- Purchase Price Range: Highest price paid was 1,461 pence per share; lowest price paid was 1,442 pence per share.
- Treasury Shares Held: 504,215,427 shares (9.26% of total issued share capital).
- Treasury Shares (Including Unsettled): 505,330,427 shares (10.23% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,940,819,440 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 490,000 shares for treasury. This transaction increased the percentage of total voting rights held in treasury from the prior level to 10.23% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding share buybacks.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (504,215,427 settled) against the company's latest annual report.
- Confirm the calculation of total voting rights (4,940,819,440 shares in issue) for disclosure threshold assessments.
- Check subsequent filings to determine if the 490,000 shares purchased on October 9, 2012, were cancelled or retained in Treasury.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for full financial metrics.